Using D-2-hydroxyglutarate in cerebrospinal fluid to track IDH‑mutant glioma
Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.
This project will see if levels of a tumor chemical called D‑2‑hydroxyglutarate in spinal fluid can show how IDH‑mutant gliomas respond to treatment or come back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11310742 on NIH RePORTER |
What this research studies
If you join, researchers will collect cerebrospinal fluid (CSF) over time using routine lumbar punctures or existing clinical CSF access devices to measure D2‑HG levels. They will compare those CSF measurements to chemical levels found directly in the tumor tissue and in microdialysate taken during neurosurgery. The work is phased: an initial feasibility and discovery stage will refine the methods, followed by a validation stage to test the biomarker in more patients. The goal is to create a reliable, repeatable CSF test that tracks tumor activity without relying only on imaging.
Who could benefit from this research
Good fit: Ideal candidates are patients with confirmed IDH‑mutant glioma who are having neurosurgical care or are willing and able to provide serial CSF samples and tumor tissue samples.
Not a fit: People without IDH‑mutant tumors or those who cannot undergo CSF sampling or tumor sampling are unlikely to benefit from this biomarker approach.
Why it matters
Potential benefit: If successful, this could give doctors an earlier and more precise way to spot treatment response or tumor recurrence using a CSF test.
How similar studies have performed: Previous research links D2‑HG to IDH‑mutant tumors, but using CSF D2‑HG as a routine monitoring biomarker is relatively new and still needs clinical validation.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Burns, Terry — Mayo Clinic Rochester
- Study coordinator: Burns, Terry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.